Liminal BioSciences Inc

Liminal BioSciences — Investor Presentation (May 2022)

22 slides from Liminal BioSciences's investor presentation, May 24, 2022

  1. Slide 1: Corporate Presentation

    Aiming to develop Best/First-In-Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Corporate Presentation NASDAQ: LMNL May 2022

  2. Slide 2: Safe Harbour

    Safe Harbour This presentation contains forward-looking statements about Liminal BioSciences’ objectives, strategies and businesses that involve risks and uncertainties. Forward‐looking information includes statements concerning, among other things, advancement of Liminal Biosciences’ product candid

  3. Slide 3: Liminal Introduction

    Aiming to develop Best/First In Class Novel Small Molecule Therapeutics for Inflammatory, Metabolic and Fibrotic Diseases Liminal Introduction Pipeline is positioned to deliver multiple value inflection milestones in 2022/23 Intellectual Property (IP) all under the control of Liminal Progressing Div

  4. Slide 4: Experienced management team

    LMNL is led by a strong, experienced team with proven track records in the discovery, development, and approval of biopharmaceuticals, all driven to make a difference. Management Team Bruce Pritchard Chief Executive Officer Executive Finance Positions: Prometic Life Sciences Inc., CV Therapeutics In

  5. Slide 5: Focus on compelling biological mechanisms and value creation

    At Liminal, we are focused on elucidating compelling biological mechanisms and plan to advance a pipeline of small molecule therapeutics with best/first-in-class potential across a broad range of significant commercial opportunities. Compelling Biological Mechanisms Data-Driven. Dedicated. We focus

  6. Slide 6: Pipeline overview: fezagepras, GPR84, OXER1

    The conjugation of fezagepras with glutamine shows that fezagepras has the potential to act as a “nitrogen scavenging” drug. Nitrogen scavenger drugs are used in the treatment of conditions characterized by hyperammonaemia such as Urea Cycle Disorders and Hepatic Encephalopathy. Fezagepras The GPR84

  7. Slide 7: Pipeline status and expected milestones

    Completed a Multiple Ascending Dose (MAD) clinical trial which provided support for the hypothesis that fezagepras has nitrogen scavenging properties. First subject dosed in Phase 1a Single Ascending Dose (SAD) clinical trial designed as a head-to-head comparison with Sodium Phenylbutyrate in May 20

  8. Slide 8: Our Lead Candidate: Fezagepras

    Our Lead Candidate: Fezagepras

  9. Slide 9: Fezagepras clinical history and nitrogen scavenging

    In December 2020 the Company initiated a Phase 1 Multiple Ascending Dose (MAD) trial in Fezagepras with a view to proceed with a Phase 2 clinical trial in fibrosis. By mid-2021, based on preliminary PK data from the Phase 1 MAD clinical trial, the Company announced its plan to discontinue the develo

  10. Slide 10: Fezagepras: Near-term Clinical Development Plan

    Fezagepras: Near-term Clinical Development Plan * Follow on clinical trials subject to result of Phase 1a SAD and relevant regulatory approvals Established baseline safety & PK profile Completed Phase 1 MAD Phase 1a SAD Phase 1a MAD Phase 1b SMAD Timing Study Goal Early Biomarker Data Dose Selection

  11. Slide 11: Our Early-Stage Candidates

    Our Early-Stage Candidates

  12. Slide 12: GPR84 antagonist

    GPR84 antagonist

  13. Slide 13: GPR84: Role in Inflammation and Fibrosis

    GPR84: Role in Inflammation and Fibrosis = GPR84 = agonist Neutrophil Monocyte/Macrophage ROS = Reactive oxygen species Pro-inflammatory/ Pro-fibrotic Activity GPR84 Agonists Pro-inflammatory cytokines Oxidative burst / ROS Chemotaxis Inflammatory conditions increase GPR84 expression

  14. Slide 14: GPR84 Receptor

    GPR84 Receptor Primarily expressed in immune cells Plays a key role in the linkage and regulation of the inflammatory and metabolic response Promotes fibrosis Antagonism of the GPR84 receptor proposes a potentially novel therapy for disease processes characterized by immunometabolism dysfunction suc

  15. Slide 15: Next steps for GPR84

    Next steps for GPR84 Commence enabling studies for regulatory approval of clinical trial File for regulatory approval for clinical trial 2023 Commence first-in-human clinical trial 2022 Preclinical candidate selection

  16. Slide 16: OXER1 Antagonist

    OXER1 Antagonist

  17. Slide 17: OXER1: Role in Tissue Repair and Inflammation

    OXER1: Role in Tissue Repair and Inflammation OXER1 is a GPCR receptor which is mainly expressed in inflammatory cells ​ Predominantly in eosinophils where the relative expression when compared to neutrophils and macrophages is 200:6:1 respectively. ​ OXER1 is specific for the ligand 5-oxo-ETE which

  18. Slide 18: Eosinophils: Both Effector and Immune-Regulator Cells

    Eosinophils: Both Effector and Immune-Regulator Cells Eosinophils are major effector cells in the immune system Part of the innate immune system; traditionally recognised as the first line of defence against parasitic infections When activated, they release a cocktail of toxic proteins along with cy

  19. Slide 19: Eosinophils in Disease

    Eosinophils in Disease Gastrointestinal Diseases Respiratory Diseases Other Diseases Skin Diseases Eosinophils are involved in acute and chronic inflammation and play an important role in a large number of allergic, inflammatory and proliferative diseases. Both eosinophils and mast cells are involve

  20. Slide 20: Development Rationale & Opportunities in Eosinophil-related Diseases

    Development Rationale & Opportunities in Eosinophil-related Diseases Eosinophil-targeting biology proven with existing, approved, monoclonal antibody drugs Reducing eosinophil levels shown to improve outcomes in severe asthma Blood eosinophil levels offer an easy-to-measure biomarker for early-stage

  21. Slide 21: Expected Milestones

    Expected Milestones Fezagepras Q2 2022: Phase 1a SAD Clinical trial H2 2022: Update on the outcome of this additional research and provide update on determining any potential new target diseases H2 2022: Market update on any further development plans for fezagepras GPR84 2022: Pre-clinical Candidate

  22. Slide 22: Financed to Deliver on Expected Milestones

    All figures presented in this section are in Canadian dollars unless otherwise specified. Financed to Deliver on Expected Milestones Cash as of March 31, 2022 $61.2M Cash Runway sufficient to support program-related milestones described on slide 21 Ongoing opportunity to monetise non-core assets Acc

Liminal BioSciences — Investor Presentation (May 2022) on 6ix